Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Berotralstat Hydrochloride Patent Expiration

Berotralstat Hydrochloride is Used for preventing attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. It was first introduced by Biocryst Pharmaceuticals Inc in its drug Orladeyo on Dec 3, 2020.


Berotralstat Hydrochloride Patents

Given below is the list of patents protecting Berotralstat Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Orladeyo US10125102 Human plasma kallikrein inhibitors Apr 07, 2035 Biocryst
Orladeyo US10329260 Human plasma kallikrein inhibitors Mar 09, 2035 Biocryst
Orladeyo US10662160 Crystalline salts of a plasma kallikrein inhibitor Nov 01, 2039 Biocryst
Orladeyo US10689346 Human plasma kallikrein inhibitors Mar 09, 2035 Biocryst
Orladeyo US11117867 Crystalline salts of a plasma kallikrein inhibitor Nov 01, 2039 Biocryst
Orladeyo US11230530 Human plasma kallikrein inhibitors Mar 09, 2035 Biocryst
Orladeyo US11618733 Crystalline salts of a plasma kallikrein inhibitor Nov 01, 2039 Biocryst
Orladeyo US11708333 Human plasma kallikrein inhibitors Mar 09, 2035 Biocryst


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳